Format

Send to

Choose Destination
Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

Author information

1
a Department of Oncology , Sidney Kimmel Cancer Center , Baltimore , MD , USA.
2
b Yale Cancer Center, Yale University , New Haven , CT , USA.
3
c Leukemia Program, Cleveland Clinic Taussig Cancer Institute , Cleveland , OH , USA.
4
d Hematologic Malignancies, H. Lee Moffitt Cancer Center , Tampa , FL , USA.
5
e Adult Leukemia Program, Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.
6
f Weill Medical College of Cornell University, Leukemia Program , New York , NY , USA.
7
g MD Anderson Comprehensive Cancer Center , Houston , TX , USA.

Abstract

First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher-risk MDS treated with AZA or DAC. DAC-treated patients (35% of females, 31% of males) had marginally better OS than AZA-treated patients (p = .043), (median OS of 18.7 months versus 16.4 months), but the difference varied strongly by sex. Female patients treated with DAC had a longer median OS (21.1 months, 95% CI: 16.0-28.0) than female patients treated with AZA (13.2 months, 95% CI: 11.0-15.9; p = .0014), while for males there was no significant difference between HMAs (median OS 18.3 months with DAC versus 17.9 months for AZA, p = .59). The biological reason for this variability is unclear, but may be a consequence of differences in cytidine deaminase activity between men and women.

KEYWORDS:

MDS; Sex; azacitidine; decitabine; hypomethylating agents

PMID:
27774847
PMCID:
PMC5394924
DOI:
10.1080/10428194.2016.1246726
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center